Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 5:09 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 601–624 of 1,229 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: TBL 12 Clear all

Conditions: Atopic Dermatitis (AD)
Interventions: ENV-294, Placebo; Drug
Lead sponsor: Enveda Therapeutics; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 32
States / cities: Birmingham, Alabama • Hot Springs, Arkansas • Beverly Hills, California + 27 more

Conditions: Infection, Human Immunodeficiency Virus
Interventions: GSK1265744 Oral, GSK1265744 LAP 800mg intramuscular injection, GSK1265744 LAP 200mg subcutaneous injection, GSK1265744 LAP 200mg intramuscular injection, GSK1265744 LAP 400mg intramuscular injection, TMC278 LA 1200mg intramuscular injection, TMC278 LA 600mg intramuscular injection; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 43 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 2
States / cities: Daytona Beach, Florida • Overland Park, Kansas

Conditions: Chronic HCV Infection
Interventions: LDV/SOF, SOF, RBV; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 13
States / cities: Sacramento, California • San Diego, California • San Francisco, California + 9 more

Conditions: Healthy
Interventions: Ticagrelor Oral Tablet - Pre-Treatment, Aspirin (ASA) Oral Tablet - Pre-Treatment, Bentracimab (PB2452) Infusion, Placebo (0.9% Sodium chloride) infusion; Drug
Lead sponsor: SFJ Pharmaceuticals, Inc.; Industry
Eligibility: 50 Years to 80 Years
Enrollment: 207 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 13
States / cities: Rogers, Arkansas • Cypress, California • San Diego, California + 9 more

Conditions: Alcohol Dependence
Interventions: Prazosin Tablet, Placebo Tablet; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2019
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Dietary Exposure
Interventions: Vitamin C gummy, Vitamin C tablet; Dietary Supplement
Lead sponsor: Church & Dwight Company, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Princeton, New Jersey

Conditions: Epilepsy
Interventions: Lacosamide Tablet, Lasosamide Oral Solution, Placebo Tablet, Placebo Oral Solution; Drug · Other
Lead sponsor: UCB BIOSCIENCES, Inc.; Industry
Eligibility: 4 Years and older
Enrollment: 242 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 27
States / cities: Alabaster, Alabama • Little Rock, Arkansas • Irvine, California + 23 more

Conditions: Erectile Dysfunction, Lower Urinary Tract Symptoms
Interventions: Placebo, Alfuzosin; Drug
Lead sponsor: Chesapeake Urology Research Associates; Other
Eligibility: 30 Years to 69 Years · Male only
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 4
States / cities: Baltimore, Maryland • Glen Burnie, Maryland • Towson, Maryland

Conditions: Breast Cancer, Prostate Cancer, Lung Cancer, Colon Cancer, Melanoma of Skin, Endometrial Cancer, Liver Cancer, Pancreatic Cancer, Rectal Cancer, Kidney Cancer, Other Solid Malignant Tumors
Interventions: Metformin, Coach Directed Behavioral Weight Loss, Self-control weight loss; Drug · Behavioral
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Irritable Bowel Syndrome
Interventions: Pregabalin, Placebo; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 70 Years
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 2
States / cities: Rochester, Minnesota • La Crosse, Wisconsin

Conditions: HIV-1 Infection
Interventions: Pravastatin sodium, Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate; Drug
Lead sponsor: Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections; Network
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 9
States / cities: Los Angeles, California • Torrance, California • St Louis, Missouri + 6 more

Conditions: Cardiovascular Diseases, Blood Pressure Disorders, Vasodilation, Platelet Aggregation
Interventions: Korean Red Ginseng Extract Powder 120 mg/tablet, Korean Red Ginseng Extract Powder 500 mg/tablet, Placebo; Dietary Supplement
Lead sponsor: Korea Ginseng Corporation; Industry
Eligibility: 20 Years to 75 Years
Enrollment: 108 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Tarzana, California

Conditions: Insomnia
Interventions: Eszopiclone, Placebo; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 65 Years to 85 Years
Enrollment: 388 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 82
States / cities: Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 69 more

Conditions: Physical Activity
Interventions: Metformin, Placebo, Carbohydrate Beverage, Protein Beverage; Drug · Dietary Supplement
Lead sponsor: Colorado State University; Other
Eligibility: 55 Years and older
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Fort Collins, Colorado

Conditions: Healthy
Interventions: lomitapide, EE/norgestimate; Drug
Lead sponsor: Aegerion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Polycystic Ovary Syndrome
Interventions: Metformin 500 mg tablet; Drug
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 2
States / cities: Charlottesville, Virginia • Richmond, Virginia

Conditions: Hepatitis C Virus
Interventions: SOF, RBV; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Hypercholesterolemia
Interventions: Atorvastatin, Ezetimibe, Alirocumab, Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 314 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 41
States / cities: Anaheim, California • Beverly Hills, California • Mission Viejo, California + 38 more

Conditions: Kidney Transplantation, Kidney Disease
Interventions: Alemtuzumab, Sirolimus, Tacrolimus, Kidney transplant, Methylprednisolone (or equivalent), Acetaminophen, Diphenhydramine, Trimethoprim (TMP)/Sulfa (Bactrim, Septra), Valgancyclovir, Acyclovir, Pentamidine, Clotrimazole, Nystatin; Drug · Procedure
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 65 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2010
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Obstetric Labour, Premature
Interventions: Retosiban, EFZ 600 mg; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Embryo Transfer
Interventions: Epelsiban; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Clonal Cytopenia of Undetermined Significance, Cytopenia
Interventions: Inqovi; Drug
Lead sponsor: Lachelle D. Weeks, MD, PhD; Other
Eligibility: 18 Years and older
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Glioblastoma
Interventions: Photon Beam Radiation Therapy, Proton Beam Radiation Therapy, Temozolomide; Radiation · Drug
Lead sponsor: NRG Oncology; Other
Eligibility: 18 Years and older
Enrollment: 624 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2030
U.S. locations: 230
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 179 more

Conditions: Dysmenorrhea, Chronic Pelvic Pain, Pelvic Pain
Interventions: Naproxen Sodium 550mg, Placebo, Extended Release Acetaminophen (650 mg); Drug
Lead sponsor: Endeavor Health; Other
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Evanston, Illinois

Search by objective public record fields.

Study of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Repeat Dose Administration of Long-Acting GSK1265744 and Long-Acting TMC278 Intramuscular and Subcutaneous Injections in Healthy Adult Subjects

Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination and Sofosbuvir + Ribavirin for Subjects With Chronic Hepatitis C Virus (HCV) and Inherited Bleeding Disorders

Phase 2B Study to Evaluate the Efficacy of Bentracimab (PB2452) in Reversal of Ticagrelor in Subjects Aged 50-80 Years Old

Prazosin to Reduce Stress-Induced Alcohol/Drug Craving and Relapse

Bioequivalence Study on Vitamin C in Healthy Adults

A Study to Assess the Safety and Efficacy of Lacosamide Versus Placebo (a Pill Without Active Medication) in Patients With Idiopathic Generalised Epilepsy Who Are Already Taking Anti-epileptic Medications

An Efficacy Study to Evaluate Alfuzosin to Treat Men With Erectile Dysfunction and Mild Lower Urinary Tract Symptoms

Survivorship Promotion In Reducing IGF-1 Trial

A Placebo-Controlled Trial of Pregabalin (Lyrica) for Irritable Bowel Syndrome

Effect of HAART Vs. Statin Treatment on Endothelial Function and Inflammation/Coagulation

Effect of Korean Red Ginseng Extract on Blood Flow in Healthy Adults

A Long-Term Safety and Efficacy Study of Eszopiclone in Elderly With Primary Chronic Insomnia

Milk Protein Feeding After Aerobic Exercise in Older Adults With Pre-diabetes Taking the Biguanide Metformin

Evaluate the Effect of Ethinyl Estradiol/Norgestimate on the Pharmacokinetics of Lomitapide in Healthy Female Subjects

Pharmacogenetics of Metformin Action in PCOS

Sofosbuvir Plus Ribavirin in Treatment-Naive and Treatment-Experienced Egyptian Adults With Chronic Genotype 4 Hepatitis C Virus (HCV) Infection

Study of Alirocumab (REGN727/SAR236553) in Patients With Primary Hypercholesterolemia and Moderate, High, or Very High Cardiovascular (CV) Risk, Who Are Intolerant to Statins (ODYSSEY ALTERNATIVE)

Combination Immunosuppressive Therapy to Prevent Kidney Transplant Rejection in Adults

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Retosiban (GSK221149) When Dosed With Efavirenz (EFZ)

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Epelsiban in Healthy Female Volunteers

Early Intervention in High Risk CCUS

Dose-Escalated Photon IMRT or Proton Beam Radiation Therapy Versus Standard-Dose Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma

NSAID Use for Treating Dysmenorrhea and Preventing Chronic Pelvic Pain (NSAID HEAL)